Investigators say they've designed a new-and-improved antibiotic

Francesc Rabanal

Francesc Rabanal, a professor in the Department of Organic Chemistry of the University of Barcelona, has spearheaded work on a new prototype compound that he says shows clear activity against both Gram-negative and Gram-positive bacteria.

The research team says they were "inspired" by natural antimicrobial peptides--particularly polymyxins. The polypeptide antibiotic is produced by a Bacillus polymyxa strain but is linked to toxicity issues that make it difficult to work with. The researchers used a disulfide bond in the structure of polymyxin that helped control toxicity.

"The main objective of the study was to design cyclic lipopeptides with a chemically accessible structure, high activity and low toxicity," says Rabanal. "The next step is to optimize this prototype compound in order to obtain a therapeutic candidate that could be developed in clinical trials and get the market."

The advantage for this new series of antibiotics is that it promises to fight drug-resistant strains of Gram-negative bacteria that pose a lethal and growing threat. But they also work against Gram-positive bacteria as well.

There's been more attention on antibiotics in the industry over the past few years, with big outfits like Merck ($MRK) and Roche ($RHHBY) investing in the field while a number of much smaller biotechs have been laboring on their own candidates. But this renewed effort follows a lengthy drought in the clinic that has left physicians with a relatively small weapons cache to fight some deadly pathogens.

- here's the release

Suggested Articles

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.